Pharma and biotech companies: Don’t just merge, innovate

By Patrick Skerrett April 20, 2016

Reprints

APStock

Editor’s note: This article was mistakenly published. It has been removed from the website.

About the Author Reprints

Patrick Skerrett

Editor, First Opinion

Patrick Skerrett is the editor of First Opinion, STAT's platform for perspective and opinion on the life sciences writ large, and the host of the First Opinion Podcast.

[email protected]

@PJSkerrett

Tags

innovation

mergers

pharmaceutical industry

Pharma and biotech companies: Don’t just merge, innovate

Patrick Skerrett

Tags

3D bioprinting can help end organ transplant waitlists — if the FDA stops delaying

Why a controversial decision won’t stop me from serving on FDA advisory committees

A surprising pandemic side effect: People are more engaged with their health

Listen: Two Alzheimer’s experts with opposing viewpoints on Aduhelm

6 ways the FDA’s approval of Aduhelm does more harm than good

About the Author Reprints

Patrick Skerrett

Tags

More in First Opinion

3D bioprinting can help end organ transplant waitlists — if the FDA stops delaying

Why a controversial decision won’t stop me from serving on FDA advisory committees

A surprising pandemic side effect: People are more engaged with their health

Listen: Two Alzheimer’s experts with opposing viewpoints on Aduhelm

6 ways the FDA’s approval of Aduhelm does more harm than good